个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm plus NSCLC

| 认领 | 导出 | |

文献详情

资源类型：
作者：
Schuler, M.[1] * ; Yang, J. C.[2,3] ; Sequist, L.[4,5] ; Wu, Y.[6] ; Zhou, C.[6] ; Geater, S.[7] ; Mok, T.[8] ; Tan, E.[9] ; Hu, C.[10] ; Yamamoto, N.[11] ; Feng, J.[12] ; O'Byrne, K.[13,14] ; Lu, S.[15] ; Hirsh, V.[16] ; Huang, Y.[17] ; Ellis, S.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21] ; Samuelsen, C.[18] ; Marten, A.[18] ; Fan, J.[19] ; Park, K.[20] ; Paz-Ares, L.[21] ;
机构： [1]Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany [2]Natl Taiwan Univ Hosp, Taipei, Taiwan [3]Natl Taiwan Univ, Taipei, Taiwan [4]Massachusetts Gen Hosp, Boston, MA 02114 USA [5]Harvard Med Sch, Boston, MA 02115 USA [6]Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China [7]Prince Songkla Univ, Hat Yai, Thailand [8]Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Peoples R China [9]Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore [10]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China [11]Wakayama Med Univ, Wakayama, Japan [12]Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China [13]Princess Alexandra Hosp, Woolloongabba, Qld, Australia [14]Queensland Univ Technol, Brisbane, Qld, Australia [15]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Tumor Clin Med Ctr, Shanghai, Peoples R China [16]McGill Univ, Montreal, PQ, Canada [17]Kunming Med Univ, Affiliated Hosp 3, Yunnan Tumor Hosp, Kunming, Yunnan, Peoples R China [18]Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany [19]Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA [20]Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea [21]Hosp Univ Doce Octubre & Cnio, Madrid, Spain
出处：
DOI： 10.1016/j.jtho.2017.09.1467
ISSN：

关键词： long-term responders PROs afatinib

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
第一作者：
第一作者机构： [1]Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
推荐引用方式(GB/T 7714)：
Schuler M.,Yang J. C.,Sequist L.,et al.Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm plus NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2017,12(11):S2210-S2210.doi:10.1016/j.jtho.2017.09.1467.
APA：
Schuler, M.,Yang, J. C.,Sequist, L.,Wu, Y.,Zhou, C....&Paz-Ares, L..(2017).Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm plus NSCLC.JOURNAL OF THORACIC ONCOLOGY,12,(11)
MLA：
Schuler, M.,et al."Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm plus NSCLC".JOURNAL OF THORACIC ONCOLOGY 12..11(2017):S2210-S2210

相关文献

[1]First-line afatinib for advanced EGFR mutation-positive (EGFRm plus ) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials [2]Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC [3]Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged >= 75 Years: Subgroup Analysis of LUX-Lung 7 [4]Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS [5]Afatinib vs gefitinib for treatment-naive patients with EGFRm1 NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment [6]Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma [7]First-Line Afatinib versus Gefitinib in EGFRm plus Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 [8]Early PROs After Uniportal Thoracoscopic Lobectomy vs Da Vinci Robotic-assisted Thoracoscopic Lobectom [9]Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. [10]Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号